Skip to main content

India Is Well-Poised to Lead the Global API Industry

Despite the uncertain global economic climate, the growth momentum for generic drug spending will continue says Catherine Tang, Biomedical industry practice leader for the Spire Research and Consulting. Its share of total drug spending is set to increase. Demand growth, primarily from emerging markets, is being accelerated by healthcare reforms in the major developed markets of USA and Europe; as well as impending patent cliffs, where some USD 75 billion worth of drugs go off patent between 2012 and 2015. This presents new potential for manufacturers of API and drug intermediates (active pharmaceutical ingredients and excipient components used in generic formulations) in India. 

India is well-poised in the global API industry, but headwinds from higher export barriers and increased pharma co-vigilance are major threats that will inevitably raise production costs and erode margins. To retain its pole position in the competitive generic market and claim blue sky space, API manufacturers need to relook business processes to operate more efficiently. And to keep Indian drugs on the world-stage amidst rising defaults on quality, India-based API manufacturers should invest in branding to make made-in-India drugs more acceptable globally.

What would make India the No1 producer of APIs?


Assurance of quality has to be the uppermost priority, given the new requirements from Europe. Indian drug manufacturers will need a quality assurance and branding strategy to complement its current low-cost value proposition. 

In light of increased FDA inspections, companies might adopt technology to automate process data collection such that the complex manufacturing processes can be better managed. Investing in information management systems will help optimize workflow, derive better quality metrics and ensure adequacy of audit trails.

The current physical infrastructure for inbound logistics has a direct impact on competitiveness. In this regard, India is out-competed by other global drug production hubs like Singapore, Ireland and Puerto Rico. The government has a role to play here in nurturing the industrial infrastructure for API production, taking a leaf from what Singapore has done with its Tuas biomedical park.

API manufacturers should also consider backward integration to reduce reliance on the import of raw materials from China and other countries. Product registration fees and other forms of levies applicable to Indian API exporters warrant concrete mitigation strategies in order for India to remain competitive on the world stage.

As the #3 exporter of generic drugs, Indian drug makers and pharma labs continue to receive strategic support from the government and industry councils. But new challenges on the blue-sky horizon call for the financial assistance provided by the government to expand so as to support upstream investment in process automation especially information management systems. 

Lastly, Indian exporters should reach out to emerging markets with messages not only on cost-effective medicines but also value co-creating initiatives that encourage collaborative strategies with destination countries and companies.

Where are we lagging behind? 

The growth of Indian companies in the pharma industry is handicapped by differential laws and regulation within India itself. The industry would benefit from a consolidation of the API manufacturers so that benefits of scale can be reaped. Lastly, more efforts are needed to raise the global customer confidence level associated with made-in-India drugs.


About Catherine Tang:

Catherine Tang is the biomedical industry practice leader for the Spire Research and Consulting group. She has over 18 years of experience in this sector, having previously worked for Boston Scientific and Medtronic, among other firms. Her career experience ranges across advanced wound therapeutics, heart valves and cardiothoracic devices to non-invasive therapies for gastroenterology, cardiology and urology. Catherine holds an MBA degree from the National University of Singapore and a BBA degree (Dean’s List) from Curtin University of Technology.


Links to coverage:











Comments

Popular posts from this blog

The European Union-Vietnam Free Trade Agreement (EVFTA) is set to open doors for Vietnamese exporters

On 30 June, 2019, the European Union signed its first free trade deal with a developing Asian country – Vietnam, one of the fastest growing economies in Southeast Asia. The EU-Vietnam Free Trade Agreement (EVFTA) would reduce 99% of tariffs on goods and services traded between European and Vietnamese markets. WVietnam’s exports to the EU were valued at 50 billion euros in 2018. This figure is expected to increase by 40% by 2025 under EVFTA. Between the years 2024 – 2028, the agreement would boost Vietnam’s gross domestic product by 5 to 6% annually. Will the EVFTA herald a closer economic relationship between Vietnam and Europe? For more information :  https://www.spireresearch.com/newsroom/spirethoughts/the-european-union-vietnam-free-trade-agreement-evfta-is-set-to-open-doors-for-vietnamese-exporters/

2022: Recovery or Resurgence?

  The Covid-19 pandemic officially marks a grim second year this year. Nonetheless, there is some optimism among scientists that while the virus will become endemic, its threat to human life could reduce over time.  In the first of a three-part Spirethoughts instalment examining analysts’ predictions for the new year ahead, we look at 3 economic and social trends that are likely to affect the global economy in 2022.   Debt and inflation to grow . Global debt accelerated during the pandemic as governments continued to borrow. Twenty-five nations, including the US and China, now have total debt amounting to more than 300% of GDP, as central banks contribute to inflation by printing money, deepening the debt trap. Inflation, while on the rise, seems unlikely to hit the historic double-digit levels of the 1970s, as government spending should ease in 2022.   Industries overheat amid global warming “greenflation”.  The other continuing story with global imp...

Spirethoughts: Saving India’s farmers

Rural farming in India could benefit immensely from solar energy, as farmers can use water pumps that are powered by solar panels to irrigate farms; balancing out the electricity provided for urban dwellers in the process. This is crucial as approximately 18 million of the country’s 25 million water pump sets are linked to the national electric grid. To address the nation’s power shortage, a joint-venture will be formed between six state-owned companies in Mumbai, including Bharat Heavy Electricals Ltd and Power Grid Corporation of India Ltd, to build a 4-gigawatt solar photovoltaic farm by the end of 2016. The price would be INR10 cheaper than the lowest power bid in India. Once the government grant has been received, this would change the way clean energy is generated; providing light through solar energy to 70 percent of the population residing in the urban areas. Is solar energy becoming a transformative resource for rural farmers? http://www.spireresearch.com/ne...

China’s landfills: Can waste be turned into energy?

260 million used tires are dumped in landfills all over the world. These tires contaminate groundwater and create clouds of black grime when they ignite, releasing toxins into the atmosphere. IFW Recycling Corporation based in the U.S. sees these old tires as a clean, green and efficient source of fuel. The tires are gassed to result in usable diesel fuel. This does not cause pollution and creates by-products for further use such as distilled water, carbon black and ash. With China emerging as one of the world’s biggest polluters, its government is seeking alternatives to coal-fired electricity generation. This could be one of them. https://www.spireresearch.com/newsroom/spirethoughts/chinas-landfills-can-waste-be-turned-into-energy/
Confidence key to Singapore’s success Can Singapore cultivate a culture of confidence as it turns 53? Leon Perera, CEO of Spire Research and Consulting shared his insights in The Business Times – Views from the Top section on 6 August 2018 on Singapore’s future. As Singapore ushers in another year of independence, more confidence needs to be instilled. Intelligent risk-taking will be key to the next phase of Singapore’s development. Perera highlighted that familiarity with past successes should not inhibit fresh, innovative thinking and experimentation with new strategies. Therefore, it is crucial for leaders to inspire trust and also for Singaporeans to cultivate greater trust in one another to be good citizens, thus engendering the social capital necessary for national success. The text of Perera’s comments are provided below. A comprehensive Korean peace treaty and denuclearization agreement are worthwhile goals to pursue. But it is unlikely that the North ...